DURHAM, N.C., Feb. 23, 2015 /PRNewswire-iReach/ -- Health Decisions, Inc., the full-service clinical research organization of choice for forward-looking biopharma and medical device companies, today announced that it will team with DynPort Vaccine Company LLC (DVC) to provide clinical development services on a contract recently awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The prime contract awarded to DVC, a Computer Sciences Corporation (CSC) company, could be up to $90 million over 10 years, depending on the number of task orders awarded. Services under the contract will support Phase 1 clinical trials of infectious disease therapeutics.
“We are delighted to work with DVC as a valued partner on this large contract to conduct infectious disease clinical trials in support of NIAID,” said Stephen DeCherney, MD, MPH, Health Decisions’ Chief Executive Officer. “Infectious disease and early phase studies are strategic areas for Health Decisions. We look forward to applying our extensive experience in these areas to help DVC and NIAID address some of the many unmet medical needs in infectious disease.”
Trials under the contract will test investigational products to protect against viral (other than HIV), bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.
As the prime contractor, DVC will manage the overall program and clinical operations, quality assurance and co-development of protocols and concepts. Health Decisions will provide clinical research and support services for the implementation and conduct of approved clinical trial protocols.
In addition to conducting numerous clinical trials in phases 1 4 for biopharmaceutical and medical-device companies, Health Decisions has a successful track record supporting other large government contracts. For example, Health Decisions will serve through 2019 as Statistical and Clinical Coordinating Center for NIH’s National Institute of Child Health and Human Development (NICHD). Under the NICHD contract, Health Decisions will conduct a variety of clinical trials of female and male contraceptives.
About Health Decisions
Health Decisions is the CRO of choice for forward-looking biopharma and medical device companies and a driving force in the modernization of clinical development. Health Decisions uses data-driven insight and agility to deliver clinical development success, reduce timelines and risk and increase quality and returns for biopharma and medical device companies worldwide. For 25 years and in more than 300 clinical trials involving tens of thousands of patients in many therapeutic areas, Health Decisions has improved the efficiency of clinical development through innovative methodology, processes and technology as reflected in Health Decisions’ winning awards including the 2013 CIO 100 Award and 2014 Association of Clinical Research Professionals Innovation in Clinical Research Award. Health Decisions’ clinical-development services consistently enable biopharma and device companies to bring new products to market faster and at lower cost, thus providing the public with earlier access to improved treatments and diagnostics at more affordable prices. Health Decisions is headquartered in Durham, NC and operates on five continents.
This project has been funded in whole or in part with Federal (United States Government) funds from the National Institute of Allergy and Infectious Diseases (NIAID), Division of Microbiology and Infectious Diseases (DMID), under contract Number HHSN272201500005I. Pursuant to section 507 of P.L. 104-208 and Section 508 of P.L. 105-78, 100% of the total of this project’s costs are financed with Federal funds. The content of this publication does not necessarily reflect the views or policies of the United States Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
Media Contact:Leslie Hammill, Health Decisions, 9199671111 ext. 520, lhammill@healthdec.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Health Decisions, Inc.
Help employers find you! Check out all the jobs and post your resume.
